FOLD vs PLX

Amicus (FOLD) targets multi-billion dollar rare disease markets with approved, differentiated therapies like Galafold (Fabry) and the newly launched AT-GAA (Pompe). AT-GAA's unique mechanism offers a significant competitive edge, driving a clear path to substantial market share if commercial execution is strong. Experienced leadership and multiple catalysts, notably AT-GAA's ramp-up, support growt...

Protalix (PLX) continues to leverage its proprietary ProCellEx platform and the global partnership with Chiesi for Elfabrio in Fabry disease. Elfabrio's ongoing market uptake provides a foundational revenue stream via royalties and potential milestones. However, the core challenge for achieving 10x per-share growth within 3-5 years remains the company's financial structure. High operational cash b...